Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

被引：0
|
作者：
Milberg, Oleg [1 ]
Chiu, Joannellyn [1 ]
Hazra, Anasuya [1 ]
Upadhyay, Sameer [1 ]
Kroog, Glenn S. [1 ]
Lorenc, Karen Rodriguez [1 ]
Davis, John D. [1 ]
Dicioccio, A. Thomas [1 ]
Harnisch, Lutz O. [1 ]
Chittenden, Jason [1 ]
机构：
[1] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200109
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7056 / 7057
页数：2
相关论文
共 50 条
  • [1] Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Visser, Sandra
    Jewell, Roxanne C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1282 - 1292
  • [2] Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM)
    Polepally, Akshanth
    Badillo, Jesus D.
    de Almeida, Carla Biesdorf
    Voorhees, Peter M.
    D'Souza, Anita
    Kumar, Shaji
    Bueno, Orlando Felix
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Menon, Rajeev
    Mensing, Sven
    Engelhardt, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)
    Abdelgawad, I.
    Lon, H.
    Soltantabar, P.
    Hibma, J.
    Czibere, A.
    Wang, D.
    Elmeliegy, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S64 - S64
  • [4] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
  • [5] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
    Dosne, Anne-Gaelle
    Li, Xia
    Luo, Man Melody
    Nnane, Ivo
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Sonneveld, Pieter
    Kampfenkel, Tobias
    Carson, Robin
    Amin, Himal
    Ruixo, Juan Perez
    Zhou, Honghui
    Sun, Yu-Nien
    Xu, Yan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
  • [6] Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Ide, Takafumi
    Osawa, Mayu
    Sanghavi, Kinjal
    Vezina, Heather E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 129 - 140
  • [7] Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML
    Kang, Dongwoo
    Passarell, Julie
    Abutarif, Malaz A.
    Mendell, Jeanne
    Yin, Ophelia
    BLOOD, 2019, 134
  • [8] Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Verona, Raluca
    Pei, Lixia
    Su, Yaming
    Ouellet, Daniele
    Garfall, Alfred L.
    Krishnan, Amrita Y.
    Usmani, Saad
    Girgis, Suzette
    Zhou, Honghui
    BLOOD, 2022, 140 : 4382 - 4383
  • [9] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection
    Badawi, Mohamed A.
    Coppola, Sheryl
    Eckert, Doerthe
    Gopalakrishnan, Sathej
    Doelger, Eva
    Dobkowska, Edyta
    Kumar, Shaji K.
    Huang, Weize
    Menon, Rajeev
    Salem, Ahmed Hamed
    BLOOD, 2022, 140 : 4281 - 4282
  • [10] CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Wang, Qi
    Gosselin, Nathalie H.
    Absalon, Michael J.
    Kolb, E. Anders
    Marier, J. F.
    Alonzo, Todd A.
    Faderl, Stefan
    Cooper, Todd M.
    BLOOD, 2020, 136
12345